Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News in Brief
  • Published:

R&D spending on the rise

Nature Reviews Drug Discovery volume 13, page 566 (2014)Cite this article

Subjects

Access through your institution
Buy or subscribe

Biotech and pharmaceutical companies boosted their research and development (R&D) spending in 2013.

“The amount of capital made available by investors, particularly to earlier-stage companies, helped fuel the rebound in R&D spending,” the authors wrote. They note that 41 initial public offerings in the United States raised $3.3 billion that contributed to the boom.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: R&D spending from 2006 to 2013.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

R&D spending on the rise. Nat Rev Drug Discov 13, 566 (2014). https://doi.org/10.1038/nrd4407

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrd4407

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research